Crossmark

Postoperative therapy with infliximab for Crohn’s disease: a 2-year prospective randomized multicenter study in Japan

Crossref DOI link: https://doi.org/10.1007/s00595-018-1627-x

Published Online: 2018-01-30

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Fukushima, Kouhei

Sugita, Akira

Futami, Kitaro

Takahashi, Ken-Ichi

Motoya, Satoshi

Kimura, Hideaki

Yoshikawa, Shusaku

Kinouchi, Yoshitaka

Iijima, Hideki

Endo, Katsuya

Hibi, Toshihumi

Watanabe, Mamoru

Sasaki, Iwao

Suzuki, Yasuo
License Information

Text and Data Mining valid from 2018-01-30
More Information

Article History

Received: 19 September 2017

Accepted: 5 January 2018

First Online: 30 January 2018

Compliance with ethical standards

:

: S.M., T.H., and M.W. serve as consultants for Tanabe Mitsubishi Pharma Co., Ltd. A.S., K.F., K.T., S.M., S.Y., H.I., K.E., T.H., M.W., and Y.S. received lecture fees from Tanabe Mitsubishi Pharma Co., Ltd. All other authors have no relevant disclosures.